Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL2 interacting protein 3 pseudogene 29 (BNIP3P29) is a non-functional remnant of the BNIP3 gene located in the human genome. Annotated as a pseudogene, it does not encode a functional protein but stems from the BCL2-interacting protein family involved in apoptosis and cell death pathways[2][7]. No evidence supports therapeutic targeting, biological function, or disease association for BNIP3P29 itself. The functional protein *BNIP3* (encoded by another locus) participates in mitochondrial regulation, autophagy, and cell death, and is implicated in cancer biology[1], but BNIP3P29 does not share these attributes[2][7]. Key distinction: BNIP3P29 should not be confused with BNIP3 (BCL2/adenovirus E1B 19 kDa protein-interacting protein 3), which is a functional protein involved in cell death and survival[1]. BNIP3P29 is solely a pseudogene and not a therapeutic target or biomolecule with known function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL2 interacting protein 3 pseudogene 29 (BNIP3P29).